公开(公告)号：US20230220387A1

公开(公告)日：2023-07-13

申请号：US17789399

申请日：2020-12-25

Applicant: Kagami Inc. ,  Public University Corporation Nara Medical University ,  National Institutes of Biomedical Innovation, Health and Nutrition

Inventor： Masashi MITA ,  Rikako SUZUKI ,  Shushi NAGAMORI ,  Pattama WIRIYASERMKUL ,  Pornparn KONGPRACHA ,  Satomi MORIYAMA ,  Tomonori KIMURA

IPC: C12N15/113 ,  A61K31/192 ,  A61K31/616 ,  A61K31/465 ,  A61K31/198 ,  A61K31/197

CPC classification number: C12N15/113 ,  A61K31/192 ,  A61K31/616 ,  A61K31/465 ,  A61K31/198 ,  A61K31/197 ,  C12N2310/14

Abstract: The present invention provides a D-serine transport modifier which is characterized by controlling the transport of D-serine into and out of cells by a D-serine transporter protein, a pharmaceutical composition which comprises the same as an active component and treats or prevents diseases relating to an increase or decrease in the amount of D-serine, and a screening method of substances that control the transport of D-serine. The present invention also provides a screening method of a D-serine transporter protein.

公开(公告)号：US20190076507A1

公开(公告)日：2019-03-14

申请号：US16079918

申请日：2017-03-01

Applicant: Public University Corporation Nara Medical University

Inventor： Hiromi Sakai ,  Magohei Yamada

IPC: A61K38/42 ,  A61K38/43 ,  A61K47/16 ,  A61K47/24 ,  A61K47/28 ,  A61K47/34 ,  A61K9/127 ,  A61P7/08 ,  A61K38/17

Abstract: Disclosed is an artificial red blood cell containing purified and enriched hemoglobin that substantially has no enzymatic activity to reduce methemoglobin, transformation of the hemoglobin into methemoglobin. Provided is an artificial red blood cell which comprises: an aqueous solution that contains NADH and/or NADPH and hemoglobin; and a capsule that includes the aqueous solution, wherein the aqueous solution and the capsule substantially have no enzymatic activity to reduce methemoglobin.

公开(公告)号：US10215766B2

公开(公告)日：2019-02-26

申请号：US14969698

申请日：2015-12-15

Applicant: PUBLIC UNIVERSITY CORPORATION NARA MEDICAL UNIVERSITY ,  SYSMEX CORPORATION

Inventor： Midori Shima ,  Keiji Nogami ,  Yuka Tabuchi ,  Hiroshi Kurono

IPC: G01N33/86 ,  G01N33/49 ,  G01N21/49 ,  G01N21/75 ,  G01N21/82

Abstract: Disclosed is a blood sample determination method including: emitting light to a measurement specimen prepared by mixing a clotting time measuring reagent and a blood sample suspected to be derived from a subject having lupus anticoagulant or a coagulation factor inhibitor, to obtain optical information about an amount of light from the measurement specimen; obtaining at least one parameter regarding derivative of clot waveform, based on the obtained optical information; and determining, based on a value of the obtained parameter, whether the blood sample is suspected to be a sample derived from a subject having lupus anticoagulant or is suspected to be a sample derived from a subject having a coagulation factor inhibitor.

公开(公告)号：US20180011114A1

公开(公告)日：2018-01-11

申请号：US15512187

申请日：2015-09-24

Applicant: PUBLIC UNIVERSITY CORPORATION NARA MEDICAL UNIVERSITY ,  CHUGAI SEIYAKU KABUSHIKI KAISHA

Inventor： Keiji Nogami ,  Midori Shima ,  Tetsuhiro Soeda ,  Takehisa Kitazawa

IPC: G01N33/86 ,  C07K16/36

CPC classification number: G01N33/86 ,  C07K16/36 ,  C07K2317/31 ,  G01N2333/755 ,  G01N2333/96444 ,  G01N2333/9645 ,  G01N2800/224 ,  G01N2800/52 ,  G01N2800/56

Abstract: The inventors produced substances that neutralize the activity of a bispecific antibody having an activity of functionally substituting for FVIII, and undertook the construction of methods for measuring the reactivity of FVIII that can ensure accuracy even in the presence of this bispecific antibody. As a result, the inventors discovered that in APTT-based one-stage clotting assay, FVIII activity in the plasma of a hemophilia A patient can be evaluated accurately, and also that in APTT-based Bethesda assay, FVIII inhibitor titer in the plasma of a hemophilia A patient carrying a FVIII inhibitor can be evaluated accurately.

公开(公告)号：US20240425614A1

公开(公告)日：2024-12-26

申请号：US18548856

申请日：2022-03-03

Applicant: Nara Medical University ,  National Institutes of Biomedical Innovation, Health and Nutrition ,  Alfresa Pharma Corporation

Inventor： Masanori Matsumoto ,  Masaki Hayakawa ,  Teruhito Yasui ,  Takeharu Minamitani

IPC: C07K16/40 ,  G01N33/573

Abstract: A preparation of an antibody or an antibody derivative that can prevent or treat acquired von Willebrand syndrome (AVWS) accompanied by a disease in need of mechanical assisted circulation. The antibody or an antibody derivative has specific binding activity against ADAMTS13, von Willebrand factor (VWF) cleaving protease, which is a causative factor of the acquired von Willebrand syndrome (AVWS) in humans, and can reduce the excessive cleavage of VWF by ADAMTS13.

公开(公告)号：US20240165546A1

公开(公告)日：2024-05-23

申请号：US18282917

申请日：2022-03-18

Applicant: Toray Industries, Inc. ,  Public University Corporation Nara Medical University

Inventor： Noriyoshi Sawabata ,  Kohei Morita ,  Chiho Obayashi ,  Hirokazu Sakaguchi ,  Yoshiaki Tominaga ,  Toru Arakane ,  Satoko Morioka ,  Yohei Noda

IPC: B01D39/16 ,  A61M5/31 ,  G01N1/40 ,  G01N33/557

CPC classification number: B01D39/1692 ,  A61M5/3145 ,  G01N33/557 ,  B01D2239/10 ,  B01D2239/1208 ,  B01D2239/125 ,  B01D2239/1291 ,  B01D2257/91 ,  G01N2001/4083 ,  G01N2001/4088

Abstract: A filter having a plurality of filter pores penetrating one surface and another surface of the filter, wherein the filter pore has a first opening on the one surface and a second opening on the another surface, a ratio (L1/W1) of a major axis diameter L1 to a minor axis diameter W1 of the first opening is 1.00 or more and 1.20 or less, the minor axis diameter W1 is 7.0 μm or more and 9.0 μm or less, a ratio (L2/W2) of a major axis diameter L2 to a minor axis diameter W2 of the second opening is 1.00 or more and 1.20 or less, and a ratio (W2/W1) of the minor axis diameter W2 to the minor axis diameter W1 and a ratio (L2/L1) of the major axis diameter L2 to the major axis diameter L1 are both 1.20 or more and 1.50 or less.

公开(公告)号：US10302626B2

公开(公告)日：2019-05-28

申请号：US15791551

申请日：2017-10-24

Applicant: PUBLIC UNIVERSITY CORPORATION NARA MEDICAL UNIVERSITY ,  CHUGAI SEIYAKU KABUSHIKI KAISHA ,  SYSMEX CORPORATION

Inventor： Midori Shima ,  Keiji Nogami ,  Tomoko Matsumoto ,  Takehisa Kitazawa ,  Tetsuhiro Soeda ,  Yuka Ikeda

IPC: G01N33/49 ,  G01N33/86 ,  C12Q1/56 ,  G01N21/59 ,  G01N21/51 ,  B01L3/00

Abstract: The present invention relates to a method for evaluating coagulability of a blood specimen obtained from a subject to whom a substance having a coagulation factor VIII-substituting activity is administered. The present invention also relates to a reagent for blood coagulation analysis, a reagent kit for blood coagulation analysis, and an apparatus for blood coagulation analysis. Furthermore, the present invention relates to an apparatus and computer program for evaluating coagulability of a blood specimen.

公开(公告)号：US20180031539A1

公开(公告)日：2018-02-01

申请号：US15661313

申请日：2017-07-27

Applicant: SYSMEX CORPORATION ,  PUBLIC UNIVERSITY CORPORATION NARA MEDICAL UNIVERSITY

Inventor： Midori SHIMA ,  Keiji NOGAMI ,  Tomoko MATSUMOTO ,  Yuka TABUCHI ,  Nobuo ARAI

IPC: G01N33/49 ,  G01N21/77 ,  G01N21/82 ,  G01N35/00

CPC classification number: G01N33/4905 ,  G01N21/77 ,  G01N21/82 ,  G01N33/86 ,  G01N35/00584 ,  G01N2021/7783 ,  G01N2035/0097 ,  G01N2333/7454 ,  G01N2333/755 ,  G01N2800/224 ,  G01N2800/56 ,  G01N2800/7033

Abstract: Disclosed is a method for determining the severity of hemophilia, the method including the steps of: coagulating a blood specimen to acquire a coagulation waveform; acquiring an average change rate of a coagulation rate from the coagulation waveform; and determining the severity of hemophilia in the blood specimen based on the average change rate of the coagulation rate.

公开(公告)号：US09668658B2

公开(公告)日：2017-06-06

申请号：US13718413

申请日：2012-12-18

Applicant: OMRON HEALTHCARE CO., LTD. ,  Public University Corporation NARA MEDICAL UNIVERSITY

Inventor： Hironori Sato ,  Naoki Mori ,  Tomoko Hashimoto ,  Toshihiko Ogura ,  Shozo Takamatsu ,  Hideo Utsuno ,  Kimihiko Kichikawa ,  Hirofumi Ito

IPC: A61B5/02 ,  A61B5/024 ,  A61B5/0285 ,  A61B5/0295 ,  A61B5/00

CPC classification number: A61B5/02438 ,  A61B5/02014 ,  A61B5/02444 ,  A61B5/0285 ,  A61B5/0295 ,  A61B5/6824 ,  A61B5/6829 ,  A61B5/7225 ,  A61B5/7246

Abstract: A first calculation unit receives phase characteristics Pa(f) and Pb(f) outputted from frequency transform units, calculates a propagation time difference based on a phase difference between the two phase characteristics in a high-frequency component thereof, and calculates a pulse wave velocity by dividing a difference in the distances of vascular pathways from the heart to respective measurement areas. Meanwhile, a second calculation unit calculates a pulse wave velocity by dividing the stated difference in the distances by a appearance time difference at a predetermined position in respective pulse waveforms obtained by rendering the measurement signals Pa(t) and Pb(t) on a time axis. A comparison unit compares the pulse wave velocities, and in the case where the ratio thereof is outside a predetermined range, an evaluation result indicating that it is possible that a predetermined pathologic change is present in the vascular pathway is outputted to a display processing unit.

公开(公告)号：US09226812B2

公开(公告)日：2016-01-05

申请号：US14373173

申请日：2013-01-28

Applicant: KAWASUMI LABORATORIES, INC. ,  PUBLIC UNIVERSITY CORPORATION NARA MEDICAL UNIVERSITY

Inventor： Hiroshi Anai ,  Toshiyasu Yuba

IPC: A61F2/04 ,  A61F2/915 ,  A61F2/07 ,  A61F2/24

CPC classification number: A61F2/04 ,  A61F2/07 ,  A61F2/24 ,  A61F2/915 ,  A61F2002/041 ,  A61F2002/91575 ,  A61F2230/0008 ,  F04C2270/0421

Abstract: The purpose of the present invention is to provide a biliary stent making it possible to sufficiently exhibit a valve function while reducing the entire length of the biliary stent as compared to conventional ones. The present invention is a biliary stent (1) including a stent body (10), a tubular membrane (30) on one end of the stent body (10) and having a bile outflow port (34), and two support members (40, 50) which at one end (42, 52) are connected to the one end of the stent body (10) and at the other end (44, 54) are connected to the vicinity of the bile outflow port (34).

Abstract translation: 本发明的目的是提供一种胆道支架，使得可以充分发挥瓣膜功能，同时与传统的支架相比，可以减少胆管支架的整个长度。 本发明是一种胆管支架（1），其包括支架主体（10），在支架主体（10）的一端上的管状膜（30），并具有胆汁流出口（34），以及两个支撑构件 ，50），其一端（42,42）连接到所述支架主体（10）的一端，并且在另一端（44,45）处连接到所述胆汁流出口（34）附近。